Skip to content

Jan Spijker

20 papers in the library · 248 citations · publishing 2015-2025

Papers

Sort Most recent Most cited

A brief online mindfulness intervention: study protocol for Indonesian undergraduate students, a randomized controlled trial.

Trials May 13, 2025 Ka Yan, Nessa Ikani, Cleoputri Yusainy et al. 1 citation

Elevated levels of stress, anxiety, and depression persist among undergraduate students in Eastern countries, including Indonesia. Access to mental healthcare resources, however, remains difficult and costly for most young people. Furthermore, there is a strong tendency to avoid seeking professional help. The primary aim of this study is to investigate the effects of a brief 14-day online...

Oral esketamine for patients with severe treatment-resistant depression: Effectiveness, safety, and tolerability of a six-week open-label treatment program.

Journal of Psychopharmacology April 25, 2025 Jolien Ke Veraart, Sanne Y Smith-Apeldoorn, Annemarie van der Meij et al. 6 citations

Oral esketamine for patients with treatment-resistant depression (TRD) could offer certain advantages over other routes, such as intravenous or intranasal, but it has not been systematically studied in a real-world setting. Here we present results from a relatively large naturalistic study to evaluate the effectiveness, tolerability, and safety of oral esketamine in patients with TRD. One...

DOI: 10.1177/02698811251332831 (opens in new tab) Full text (opens in new tab) Treatment-resistant depression Oral esketamine Real-world effectiveness Mental health treatment +1

Demographic and clinical predictors of response and remission in the treatment of major depressive disorder with ketamine and esketamine: A systematic review.

Psychiatry Research March 1, 2025 Juliana Lima Constantino, Martijn Godschalk, Jens H van Dalfsen et al. 14 citations

Accumulating evidence supports the efficacy of (es)ketamine in the treatment of major depressive disorder (MDD), particularly treatment-resistant depression (TRD). Yet around 50% of the individuals with TRD do not respond to (es)ketamine. Elucidating predictors of response and remission could improve treatment outcomes at the individual level by defining subpopulations that are most likely to...

Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension.

Molecular Psychiatry September 1, 2024 Sanne Y Smith-Apeldoorn, Jolien K E Veraart, Jeanine Kamphuis et al. 23 citations

About one-third of patients with depression do not achieve adequate response to current treatment options. Although intravenous and intranasal administrations of (es)ketamine have shown antidepressant properties, their accessibility and scalability are limited. We investigated the efficacy, safety, and tolerability of generic oral esketamine in patients with treatment-resistant depression (TRD)...

Change in Mindfulness Profiles After Mindfulness-Based Cognitive Therapy for Major Depressive Disorder

Mindfulness July 1, 2024 Jelle Lubbers, Philip Spinhoven, Mira B. Cladder-Micus et al.

Abstract Objectives Mindfulness-Based Cognitive Therapy (MBCT) reduces recurrence and current depressive symptoms in patients with major depressive disorder (MDD). To understand how and for whom MBCT works, a person-centered approach focusing on mindfulness profiles can be useful. Four mindfulness profiles, each associated differently with mental health outcomes, have previously been...

Latent Profile Analysis of the Five Facet Mindfulness Questionnaire (FFMQ) Subscales in a Naturalistic Sample of Patients with Past or Present Major Depression: A Replication and Extension Study

Mindfulness February 1, 2024 Jelle Lubbers, Philip Spinhoven, Mira B. Cladder-Micus et al.

Abstract Objectives Mindfulness is a multifaceted concept which might be best captured by person-centered profiles rather than by variable-centered assessment of its subcomponents. Patients with different mindfulness profiles may vary in mental health status and might experience differential clinical outcomes of Mindfulness-Based Cognitive Therapy (MBCT). We therefore aimed to assess the...

Rumination and Self-Compassion Moderate Mindfulness-Based Cognitive Therapy for Patients With Recurrent and Persistent Major Depressive Disorder: A Controlled Trial.

Depression and Anxiety 2024 Jelle Lubbers, Dirk E. M. Geurts, Philip Spinhoven et al. 10 citations

Background: Mindfulness-based cognitive therapy (MBCT) is effective in reducing depressive symptoms in patients with major depressive disorder (MDD). Understanding for whom and how MBCT works may allow for improvements in treatment allocation and effectiveness. In this study, our aim was to investigate depressive rumination, content-independent perseverative thinking, mindfulness skills, and...

Follow-up outcomes of Mindfulness-Based Cognitive Therapy (MBCT) for patients with chronic, treatment-resistant depression.

Journal of Affective Disorders May 1, 2023 Mira B. Cladder-Micus, J. Vrijsen, A. Fest et al.

BACKGROUND Mindfulness-based cognitive therapy (MBCT) is an evidence-based treatment for depression. The current study focused on the long-term effects of MBCT for chronically, treatment-resistant depressed patients during a 6-months follow-up period. Additionally, predictors of treatment outcomes were explored. METHOD The outcomes of MBCT on depressive symptoms, remission rates, quality of...

Supporting antidepressant discontinuation using mindfulness plus monitoring versus monitoring alone: A cluster randomized trial in general practice.

PLoS One 2023 Marloes J. Huijbers, Carolien Wentink, Peter L B J Lucassen et al.

Discontinuing antidepressant medication (ADM) can be challenging for patients and clinicians. In the current study we investigated if Mindfulness-Based Cognitive Therapy (MBCT) added to supported protocolized discontinuation (SPD) is more effective than SPD alone to help patients discontinue ADM. This study describes a prospective, cluster-randomized controlled trial (completed). From 151...

Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability.

The Lancet Psychiatry November 1, 2022 Sanne Y Smith-Apeldoorn, Jolien K E Veraart, Jan Spijker et al. 163 citations

Ketamine has rapid yet often transient antidepressant effects in patients with treatment-resistant depression. Different strategies have been proposed to prolong these effects. Maintenance ketamine treatment appears promising, but little is known about its efficacy, safety, and tolerability in depression. We searched Pubmed, Embase, and the Cochrane Library and identified three randomised...

The effect of mindfulness-based cognitive therapy on rumination and a task-based measure of intrusive thoughts in patients with bipolar disorder.

International Journal of Bipolar Disorders August 12, 2022 Jelle Lubbers, Dirk E. M. Geurts, Imke Hanssen et al.

Preliminary evidence suggests that Mindfulness-Based Cognitive Therapy (MBCT) is a promising treatment for bipolar disorder (BD). A proposed working mechanism of MBCT in attenuating depressive symptoms is reducing depressive rumination. The primary aim of this study was to investigate the effect of MBCT on self-reported trait depressive rumination and an experimental state measure of negative...

DOI: 10.1186/s40345-022-00269-1 (opens in new tab) Full text (opens in new tab) Bipolar disorder Breathing focus task Depressive rumination Intrusive thoughts +2

The Effect of Mindfulness-Based Cognitive Therapy On Rumination and Intrusive Thoughts in Patients With Bipolar Disorder: Secondary Analyses From a Randomized Controlled Trial

Research Square December 30, 2021 Jelle Lubbers, Dirk E. M. Geurts, Imke Hanssen et al. preprint

Background: Preliminary evidence suggests that Mindfulness-Based Cognitive Therapy (MBCT) is a promising treatment for bipolar disorder (BD). One of the proposed working mechanisms of MBCT in attenuating depressive symptoms is through the reduction of depressive rumination. In BD the effect of MBCT on rumination is less well studied. The primary aim of this study was to investigate the effect...

Factors associated with relapse and recurrence of major depressive disorder in patients starting mindfulness‐based cognitive therapy

Depression and Anxiety November 9, 2021 J. D. de Klerk-Sluis, Marloes J. Huijbers, S. Löcke et al.

Mindfulness‐based cognitive therapy (MBCT) is effective for relapse prevention in major depressive disorder (MDD). It reduces cognitive reactivity (CR) and rumination, and enhances self‐compassion and mindfulness. Although rumination and mindfulness after MBCT are associated with relapse, the association of CR, rumination, self‐compassion, and mindfulness with relapse before initiation of MBCT...

Ketamine Treatment for Depression in Patients With a History of Psychosis or Current Psychotic Symptoms: A Systematic Review.

The Journal of Clinical Psychiatry July 13, 2021 Jolien K E Veraart, Sanne Y Smith-Apeldoorn, Jan Spijker et al. 31 citations

Objective: Ketamine shows rapid and robust antidepressant effects in clinical studies. Psychotic features are an exclusion criterion in most ketamine treatment studies based on the assumption that psychosis will increase with ketamine administration. As patients with treatment-resistant depression (TRD) often have psychotic features, and treatment-resistant depressive symptoms are also common...

Discontinuing antidepressant medication after mindfulness-based cognitive therapy: a mixed-methods study exploring predictors and outcomes of different discontinuation trajectories, and its facilitators and barriers

BMJ Open November 12, 2020 Marloes J. Huijbers, Carolien Wentink, Anne E. M. Speckens et al.

Objectives This study aimed to explore predictors and outcomes associated with different trajectories of discontinuing antidepressant medication (ADM), in recurrently depressed individuals after participation in mindfulness-based cognitive therapy (MBCT). Facilitators and barriers of discontinuation were explored qualitatively.Design Mixed-methods study combining quantitative and qualitative...

Mindfulness‐based cognitive therapy for patients with chronic, treatment‐resistant depression: A pragmatic randomized controlled trial

Depression and Anxiety August 8, 2018 Mira B. Cladder-Micus, Anne E. M. Speckens, J. Vrijsen et al.

Chronic and treatment‐resistant depressions pose serious problems in mental health care. Mindfulness‐based cognitive therapy (MBCT) is an effective treatment for remitted and currently depressed patients. It is, however, unknown whether MBCT is effective for chronic, treatment‐resistant depressed patients.

Cognitive reactivity as outcome and working mechanism of mindfulness-based cognitive therapy for recurrently depressed patients in remission.

Cognition & Emotion March 2018 Mira B. Cladder-Micus, Joël R Van Aalderen, A R T Donders et al.

Major depressive disorder is a prevalent condition with high relapse rates. There is evidence that cognitive reactivity is an important vulnerability factor for the recurrence of depression. Mindfulness-based interventions are designed to reduce relapse rates, with cognitive reactivity as one of the proposed working mechanisms. In a randomised controlled trial we compared the effect of...

Discontinuation of antidepressant medication after mindfulness-based cognitive therapy for recurrent depression: randomised controlled non-inferiority trial.

The British Journal of Psychiatry April 2016 Marloes J. Huijbers, Philip Spinhoven, Jan Spijker et al.

Mindfulness-based cognitive therapy (MBCT) and maintenance antidepressant medication (mADM) both reduce the risk of relapse in recurrent depression, but their combination has not been studied. To investigate whether MBCT with discontinuation of mADM is non-inferior to MBCT+mADM. A multicentre randomised controlled non-inferiority trial (ClinicalTrials.gov:NCT00928980). Adults with recurrent...

Adding mindfulness-based cognitive therapy to maintenance antidepressant medication for prevention of relapse/recurrence in major depressive disorder: Randomised controlled trial.

Journal of Affective Disorders November 15, 2015 Marloes J. Huijbers, Philip Spinhoven, Jan Spijker et al.

Mindfulness-based cognitive therapy (MBCT) and maintenance antidepressant medication (mADM) both reduce the risk of relapse in recurrent depression, but their combination has not been studied. Our aim was to investigate whether the addition of MBCT to mADM is a more effective prevention strategy than mADM alone. This study is one of two multicenter randomised trials comparing the combination of...

A randomized controlled trial of Mindfulness-Based Cognitive Therapy (MBCT) versus treatment-as-usual (TAU) for chronic, treatment-resistant depression: study protocol

BMC Psychiatry November 9, 2015 Mira B. Cladder-Micus, J. Vrijsen, E. Becker et al.

BackgroundMajor depression is a common psychiatric disorder, frequently taking a chronic course. Despite provision of evidence-based treatments, including antidepressant medication and psychological treatments like cognitive behavioral therapy or interpersonal therapy, a substantial amount of patients do not recover. Mindfulness-Based Cognitive Therapy (MBCT) has been found to be effective in...